Regulatory challenges
Complex approval processes for new drugs
- Materiality
- high
Medivir
Medivir AB is a Swedish pharmaceutical company focused on the development of innovative treatments for serious diseases. The company specializes in the research and development of small molecule drugs, with a particular emphasis on oncology and rare diseases. Medivir's portfolio includes both proprietary projects and outlicensed assets, allowing them to leverage partnerships for broader market reach. With a strong financial position and strategic collaborations, Medivir aims to advance its clinical projects and create long-term value for shareholders and patients alike.
10
3.66
3.64
| % | |
|---|---|
| Oncology | 40% Includes drugs for cancer treatment such as remetinostat and birinapant. |
| Rare Diseases | 30% Focuses on treatments for rare conditions like Osteogenesis Imperfecta. |
| Dermatology | 15% Includes products like Xerclear for skin conditions. |
| Veterinary Medicine | 15% Involves drugs for animal health, such as VBX-1000. |
Medivir's customer base primarily consists of pharmaceutical companies and healthcare providers seeking innovative...
- Pharmaceutical Companiesprimary
License Medivir's oncology and rare disease treatments for distribution.
- Healthcare Providerssecondary
Utilize Medivir's drugs for treating patients with rare diseases.
- Veterinary Clinicsemerging
Adopt VBX-1000 for treating canine periodontitis.
Medivir operates primarily out of Sweden, with a focus on expanding its market presence through global partnerships...
- •Headquartered in Sweden with global partnerships
- •Licensing agreements in North America and Europe
- •Currency exposure due to multi-currency contracts
- •Strategic focus on U.S. market exclusivity
Medivir's strategic priorities include advancing its clinical pipeline, particularly in oncology and rare diseases...
01
Advance clinical pipelinemedium-term
To bring innovative treatments to market
02
Leverage orphan drug designationslong-term
To secure market exclusivity and regulatory support
03
Strengthen financial positionshort-term
To support ongoing and future clinical developments
Medivir faces significant risks inherent in pharmaceutical development, including high costs and regulatory challenges...
Currency exposure
Multi-currency contracts affecting financial stability
- Materiality
- medium
Partnership performance
Dependence on partners for market access
- Materiality
- high
Revenue recognition
high
Currency fluctuations
medium
: 11/08/2026